Syrosingopine
Based on 15 publication(s) in Google Scholar
Syrosingopine (Su 3118) is an orally active lactate transporters (MCT1/MCT4) dual inhibitor, which can reduce glycolysis and induce synthetic lethality in cancer cells when combine with metformin. Syrosingopine shows anti-hypertensive activity by depleting peripheral stores of norepinephrine.
For research use only. We do not sell to patients.
- Purity: 99.52%
- CAS No.: 84-36-6
- Formula: C35H42N2O11
- Molecular Weight:666.71
-
Storage:
4°C, protect from light
* In solvent : -80°C, 2 years; -20°C, 1 year (protect from light)
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Membrane Transporter/Ion Channel Compound Library
HY-L011
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Glycolysis Compound Library
HY-L058
-
Orally Active Compound Library
HY-L061
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Glucose Metabolism Compound Library
HY-L092
-
Human Metabolite Library
HY-L123
-
Coagulation and Anti-coagulation Compound Library
HY-L136
-
Heterocyclic Compound Library
HY-L138
-
Antihypertensive Compound Library
HY-L145
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Lactic Acid Metabolic Compound Library
HY-L204
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
Publications Citing Use of MedChemExpress (MCE) Syrosingopine
More- Signal Transduct Target Ther. 2025 Oct 31;10(1):356. [Abstract]
- Cell Metab. 2025 Sep 2;37(9):1907-1925.e14. [Abstract]
- Adv Mater. 2025 Sep 15:e11348. [Abstract]
- Immunity. 2024 May 14:S1074-7613(24)00227-9. [Abstract]
- ACS Nano. 2026 Mar 10;20(9):7928-7939. [Abstract]
- Autophagy. 2026 Apr 8. [Abstract]
- Adv Sci (Weinh). 2023 Feb;10(4):e2204808. [Abstract]
- Biomaterials. 2026 Feb:325:123538. [Abstract]
- Biomaterials. 2025 Mar:314:122883. [Abstract]
- J Immunother Cancer. 2023 Jun;11(6):e006287. [Abstract]
- Cell Rep. 2026 Mar 10;45(3):117069. [Abstract]
- J Pathol. 2025 Oct 23. [Abstract]
- Int Immunopharmacol. 2024 Mar 30:130:111765. [Abstract]
- Res Sq. 2026 Jun 15.
- bioRxiv. 2025 Jul 27:2025.07.23.666216. [Abstract]
Customer Validation & Images
-
Bio/Physico-chemical Assay
-
WB
-
Cell Migration/Invasion Assay
-
ELISA
-
Flow Cytometry
Biological Activity
|
MCT1 |
MCT4 |
Syrosingopine (10 μM; 1, 3, 4 hours) causes accumulation of intracellular lactate after 1 hour and peaks at 4 hours, which lead to intracellular acidification in HeLa cells[1].
Syrosingopine (10 μM; 1, 2 hours) slows lactate efflux by inhibiting MCT4 and MCT1 in MCT1-KO and MCT4-KO HAP1 cells, respectively[1].
Syrosingopine (10-100 μM)-metformin combination induces synthetic lethality by inhibiting transport of lactate in HAP1 MCT1-KO cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HeLa, MCT1-KO, MCT4-KO HAP1, HAP1 MCT1-KO
-
Concentration:10 µM
-
Incubation Time:1, 2, 3, 4 hours
-
Result:Caused intracellular lactate accumulation and acidification.
Slowed lactate efflux by inhibiting MCT4 and MCT1.
Induced synthetic lethality by inhibiting transport of lactate when combined with metformin.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Spontaneously hypertensive rats (SHR) (2 to 17-month-age)[2].
-
Dosage:5 mg/kg
-
Administration:Subcutaneous injection; once (16 hours before undertaking the study of blood pressure).
-
Result:Showed anti-hypertensive activity by depleting peripheral stores of norepinephrine.
Chemical Information
-
CAS No. 84-36-6
-
Appearance Solid
-
Molecular Weight 666.71
-
Formula C35H42N2O11
-
Color White to yellow
-
SMILES
[H][C@@]12C(NC3=C4C=CC(OC)=C3)=C4CCN1C[C@]5(C[C@@H](OC(C6=CC(OC)=C(OC(OCC)=O)C(OC)=C6)=O)[C@H](OC)[C@@H](C(OC)=O)[C@]5(C2)[H])[H]
-
Synonyms
Su 3118
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 2 years; -20°C, 1 year (protect from light)
Publications (15)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Alpha-enolase influences ATP pool of cytoplasm and lactate homeostasis by regulating glycolysis in gastric cancer. [Abstract]2025 Oct 31;10(1):356. PMID: 41168198
Syrosingopine purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 Oct 31;10(1):356. [Abstract]
ATP and extracellular lactate were tested in PAMC82 and SNU16 cells treated with Metformin (MET; 10 μM, 48 h) and/or Syrosingopine (Syro; 20 μM, 48 h).
Syrosingopine purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 Oct 31;10(1):356. [Abstract]
Protein expression related to the PI3K/AKT and AMPK/mTOR pathways was tested in PAMC82 and SNU16 cells treated with Metformin and/or Syrosingopine (20 μM). The synergistic inhibition of cell proliferation.
Syrosingopine purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2025 Oct 31;10(1):356. [Abstract]
The combination of MET and Syrosingopine (SYRO) (20 μM) inhibited the migration in PAMC82 and SNU16 cells.
-
Cell Metab
Tumor-associated Schwann cell remodeling under metabolic stress via lactate sensing orchestrates pancreatic ductal adenocarcinoma development. [Abstract]2025 Sep 2;37(9):1907-1925.e14. PMID: 40803319 -
Adv Mater
Molecularly Engineered Nanoagents with Efficient Free Radicals Generation and Photothermal Conversion Performance for Enhanced Tumor Photoimmunotherapy via Targeting Lactate Metabolism-Immune Circuit Rewiring. [Abstract]2025 Sep 15:e11348. PMID: 40952145 -
Immunity
Metabolic coordination between skin epithelium and type 17 immunity sustains chronic skin inflammation. [Abstract]2024 May 14:S1074-7613(24)00227-9. PMID: 38772365 -
ACS Nano
A Biomimetic Microparticle Disrupting the Intracellular/Extracellular pH Homeostasis of Tumor Cells for Cancer Chemo-Immunotherapy. [Abstract]2026 Mar 10;20(9):7928-7939. PMID: 41729031 -
Autophagy
Secretory autophagy mediates SLC16A3/MCT4-dependent lactate secretion to drive metastatic progression in triple-negative breast cancer. [Abstract]2026 Apr 8. PMID: 41948828 -
Adv Sci (Weinh)
Insights into the Effect of Catalytic Intratumoral Lactate Depletion on Metabolic Reprogramming and Immune Activation for Antitumoral Activity. [Abstract]2023 Feb;10(4):e2204808. PMID: 36479819 -
Biomaterials
Lactate metabolism regulating nanosystem synergizes cuproptosis and ferroptosis to enhance cancer immunotherapy. [Abstract]2026 Feb:325:123538. PMID: 40680708 -
Biomaterials
Mitochondrial-uncoupling nanomedicine for self-heating and immunometabolism regulation in cancer cells. [Abstract]2025 Mar:314:122883. PMID: 39405827 -
J Immunother Cancer
Inhibition of lactate transport by MCT-1 blockade improves chimeric antigen receptor T-cell therapy against B-cell malignancies. [Abstract]2023 Jun;11(6):e006287. PMID: 37399358
Syrosingopine purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2023 Jun;11(6):e006287. [Abstract]
Syrosingopine (1.25, 2.5, 5, 10, 20 μM, 48 h) significantly reduced IFN-γ production in a dose-dependent manner by ELISA.
Syrosingopine purchased from MedChemExpress. Usage Cited in: J Immunother Cancer. 2023 Jun;11(6):e006287. [Abstract]
Syrosingopine (1.25, 2.5, 5, 10, 20 μM) alone reduced the number of tumor cells.
-
Cell Rep
2026 Mar 10;45(3):117069. PMID: 41811847 -
J Pathol
Lactate-mediated activation of GPR81 regulates BCR/Abl protein expression in chronic myeloid leukemia cells selected under low oxygen tension. [Abstract]2025 Oct 23. PMID: 41128634 -
Int Immunopharmacol
Lactate acid promotes PD-1+ Tregs accumulation in the bone marrow with high tumor burden of Acute myeloid leukemia. [Abstract]2024 Mar 30:130:111765. PMID: 38447414 -
-
bioRxiv
Glycogen metabolism in mouse embryonic Sertoli cells sustains the germ line through the lactate shuttle. [Abstract]2025 Jul 27:2025.07.23.666216. PMID: 40777410
Solvent & Solubility
DMSO : 62.5 mg/mL (93.74 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (protect from light). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (protect from light). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (3.12 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 2 years; -20°C, 1 year (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Benjamin D, et al. Dual Inhibition of the Lactate Transporters MCT1 and MCT4 Is Synthetic Lethal with Metformin due to NAD+ Depletion in Cancer Cells. Cell Rep. 2018 Dec 11;25(11):3047-3058.e4. [Content Brief]
[2]. Lefèvre-Borg F, et al. Role of the sympathetic nervous system in blood pressure maintenance and in the antihypertensive effects of calcium antagonists in spontaneously hypertensive rats. Hypertension. 1988 Apr;11(4):360-70. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (protect from light). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.4999 mL | 7.4995 mL | 14.9990 mL | 37.4976 mL |
| 5 mM | 0.3000 mL | 1.4999 mL | 2.9998 mL | 7.4995 mL | |
| 10 mM | 0.1500 mL | 0.7500 mL | 1.4999 mL | 3.7498 mL | |
| 15 mM | 0.1000 mL | 0.5000 mL | 0.9999 mL | 2.4998 mL | |
| 20 mM | 0.0750 mL | 0.3750 mL | 0.7500 mL | 1.8749 mL | |
| 25 mM | 0.0600 mL | 0.3000 mL | 0.6000 mL | 1.4999 mL | |
| 30 mM | 0.0500 mL | 0.2500 mL | 0.5000 mL | 1.2499 mL | |
| 40 mM | 0.0375 mL | 0.1875 mL | 0.3750 mL | 0.9374 mL | |
| 50 mM | 0.0300 mL | 0.1500 mL | 0.3000 mL | 0.7500 mL | |
| 60 mM | 0.0250 mL | 0.1250 mL | 0.2500 mL | 0.6250 mL | |
| 80 mM | 0.0187 mL | 0.0937 mL | 0.1875 mL | 0.4687 mL |
Powered by Bioz